| Date Filed | Type | Description |
| 10/11/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 10/10/2023 |
8-K
| Quarterly results |
| 10/10/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 10/06/2023 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 09/28/2023 |
S-4
| Form S-4 - Registration of securities, business combinations: |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Investor presentation |
| 08/07/2023 |
8-K
| Appointed a new director |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/08/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/26/2023 |
8-K
| Quarterly results |
| 04/17/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/03/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/30/2023 |
8-K
| Quarterly results |
| 03/29/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/29/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/29/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/17/2023 |
DEFC14A
| Form DEFC14A - Definitive proxy statement, contested solicitations: |
| 03/17/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/16/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/15/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/15/2023 |
DEFC14A
| Form DEFC14A - Definitive proxy statement, contested solicitations: |
| 03/13/2023 |
PRER14A
| Form PRER14A - Preliminary Proxy Soliciting materials: |
| 03/13/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/07/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/07/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/07/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/07/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/07/2023 |
8-K
| Investor presentation, Quarterly results |
| 03/06/2023 |
PRER14A
| Form PRER14A - Preliminary Proxy Soliciting materials: |
| 02/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 02/27/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy CELEBRATION, FL, February 27, 2023 – Zevra Therapeutics, Inc. , today announced it has filed its preliminary proxy statement with the U.S. Securities and Exchange Commission in connection with the Company’s 2023 Annual Meeting of Stockholders , which is scheduled to take place on April 25, 2023. Stockholders do not need to take any action with respect to the 2023 Annual Meeting at this time. In its preliminary proxy statement, Zevra announced that the Board has nominated three directors for re-election at the Company’s Annual Meeting — Richard W. Pascoe, David S. Tierney, M.D., and Christopher A. Posner. With the re-election of these serving directors, the Zevra Board will comprise seven highly qualified indiv..." |
|
| 02/27/2023 |
PREC14A
| Form PREC14A - Preliminary proxy statements, contested solicitations: |
| 01/20/2023 |
8-K
| Other Events Interactive Data |
|